Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PMS1
REST API REST API
Homo sapiens
PMS1 is differentially expressed in 317 experiments: 110 organism parts: testis, bone marrow, ... (108 more);, 185 disease states: normal, acute myeloid leukemia, ... (183 more);, 99 cell types 346 cell lines 46 compound treatments and 72 other conditions.
Synonyms PMSL1
Orthologs PMS1 (Saccharomyces cerevisiae)   ENSCING00000003685 (Ciona intestinalis)   PMS1 (Gallus gallus)   Pms1 (Mus musculus)   pms1 (Danio rerio)   PMS1 (Bos taurus)   D3ZPT8_RAT (Rattus norvegicus)   pms1 (Xenopus laevis)   PMS1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term reciprocal meiotic recombination, DNA binding, ATPase activity, mismatched DNA binding, ATP binding, nucleus, mismatch repair, ATP catabolic process, MutLalpha complex
InterPro Term DNA_mismatch_repair_N, DNA_mismatch_repair_C, HMG_HMG1/HMG2, ATPase-like_ATP-bd
UniProt Accession P54277, B7ZAA0, Q3BDU3, Q5XG96, C9J4L1, C9JF76, C9JKP0, Q68DF0, Q5FBZ1, Q5FBZ2, Q5FBZ6, Q5FBZ3, Q5FBZ8, Q5FBZ7, Q4VAL4, E7EQE2, E9PC65, E9PC40, E9PH88, F8W8L1
Gene-Disease Assocation POSTMEIOTIC SEGREGATION INCREASED, S. CEREVISIAE, 1; PMS1
Search EB-eye ENSG00000064933
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-MEXP-433, E-GEOD-3526, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (36 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
U87
2
E-MEXP-903, E-GEOD-20089
A549
2
E-GEOD-3202, E-GEOD-6013
MDA-MB-231
2
E-GEOD-5823, E-TABM-420
SW480
2
E-MEXP-1014, E-GEOD-18005
SKNAS
1
E-MTAB-37
340 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-21750, ... (50 experiments)

Factor Value U/D Experiments
CD8+ T cell
2
E-AFMX-5, E-TABM-145
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
1
2
E-TABM-130, E-TABM-145
alveolar space neutrophil
1
E-GEOD-2322
93 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1577, E-TABM-15, E-MEXP-2280, E-MTAB-62, ... (60 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-MEXP-2034, E-MTAB-62, E-GEOD-96
colorectal carcinoma
2
E-GEOD-23878, E-MTAB-37
Burkitt's lymphoma
2
E-MTAB-37, E-GEOD-96
astrocytoma
1
E-GEOD-4290
presymptomatic DMD
1
E-MTAB-62
T cell lymphoblast-like cell line
1
E-MTAB-62
179 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (31 experiments)

Factor Value U/D Experiments
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
AMP
1
1
E-MEXP-2285
2-(3,4,5-trimethoxy-phenylamino)-pyrrolo[2,3-d]pyrimidines
1
E-GEOD-6932
vanadium pentoxide
1
E-GEOD-5339
4,5-dianilinophthalimide
1
1
E-GEOD-5258
control - IL-1b
1
E-GEOD-7216
40 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-860, E-MEXP-1251, E-GEOD-2191, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-3013

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, E-GEOD-6431, ... (8 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-MEXP-2657, E-GEOD-20504, E-MEXP-1446, E-GEOD-22278, ... (11 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-15, ... (34 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, ... (9 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-1493, E-GEOD-22309, E-GEOD-21750, ... (6 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (6 experiments)

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-33562, E-GEOD-22368, E-GEOD-21909, E-GEOD-19246, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4271

Vehicle
studied in E-GEOD-5258

Processing time: 0.417 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM